Transactions in Own Shares

Haleon PLC

01 June 2026

 

Haleon plc: Aggregated information - transactions in own shares

1 June 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 10,149,493 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE	Aquis
Date of purchase:	26 May 2026
Number of Shares purchased:	905,222	768,112	786,713	-
Highest price paid per Share (p):	346.0000	346.0000	346.0000	-
Lowest price paid per Share (p):	341.6000	341.6000	341.6000	-
Volume weighted average price paid per Share (p):	343.1415	343.1167	343.0473	-
Date of purchase:	27 May 2026
Number of Shares purchased:	306,596	132,534	130,988	-
Highest price paid per Share (p):	344.0000	344.0000	344.0000	-
Lowest price paid per Share (p):	341.4000	341.4000	341.4000	-
Volume weighted average price paid per Share (p):	343.0269	343.0300	343.0293	-
Date of purchase:	28 May 2026
Number of Shares purchased:	1,744,909	939,106	936,881	-
Highest price paid per Share (p):	344.6000	344.4000	344.6000	-
Lowest price paid per Share (p):	340.8000	340.8000	340.8000	-
Volume weighted average price paid per Share (p):	342.1974	342.1678	342.3110	-
Date of purchase:	29 May 2026
Number of Shares purchased:	1,517,312	1,012,452	968,668	-
Highest price paid per Share (p):	342.2000	342.2000	342.2000	-
Lowest price paid per Share (p):	336.1000	336.1000	336.1000	-
Volume weighted average price paid per Share (p):	338.5963	338.6275	338.5752	-

Following the settlement of the above, the Company's registered share capital is 8,859,337,794 ordinary shares of £0.01 each, of which 12,076,964 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,847,260,830 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/3199G_1-2026-5-29.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	[phone]	Zoë Bird	[phone]
Rakesh Patel	[phone]	Victoria Durman	[phone]
Email: [e-mail]		Email: [e-mail]

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com. 

 

END